linjc16/ctgov huggingface dataset:
Outcomes of Secondary Endovascular Aortic Repair After Initial Frozen Elephant Trunk Procedure

Study Overview
=================
Brief Summary
-----------------
Objective Complex aortic pathology has been revolutionized with the use of hybrid prostheses such as the Thoraflex® Hybrid Frozen Elephant Trunk (FET). The aim of this study was to evaluate the midterm results of secondary extension of the FET by thoracic endovascular aortic repair (TEVAR). Few data are present in the literature regarding the outcomes of this secondary treatment. The investigators perform a prospective study between 2015 and 2022 in a tertiary aortic center on all consecutive patients having undergone TEVAR after FET implantation. The TEVAR endograft covered most of the 10 cm FET module with 2 to 4 mm oversizing. All patients were monitored by computerized angiography (CTA) at 6-month and yearly thereafter. The aim of this study was the feasibility of theses secondary connexion and the mid term outcomes of the endovascular treatment.

Official Title
-----------------
Outcomes of Secondary Endovascular Aortic Repair After Initial Aortic Cross Replacement by a Frozen Elephant Trunk

Conditions
-----------------
Thoraco-abdominal Aneurysm, Aortic Dissection

Intervention / Treatment
-----------------
* Procedure: Secondary TEVAR after initial FET procedure


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Patient with aortic cross replacement by FET and Type 1 and Type 2 Thoracoabdominal aneurysm (TAAA) with a diameter at > 6 cm or an aortic dissection, Type A (TAAD) or Type B (TBAD) with either organ malperfusion due to compression of the true channel or aneurysmal evolution of the dissected aorta, or A defect in the expansion of the FET module Exclusion Criteria: No aortic cross replacement by FET
Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Arms and Interventions

| Intervention/Treatment |
| --- |
|Procedure: Secondary TEVAR after initial FET procedure|Under general anesthesia, via percutaneous femoral access, the investigators implant a TEVAR in the endovascular part of a FET. This secondary connexion is indicated in case distal thoracic aortic involvement such as aneurysm or dissection.|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Absence of endoleak after secondary connexion | Absence of Type 1A endoleak | yearly thereafter up to 5 years | 

Secondary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Feasibility of the secondary connexion | Absence of failed procedure | During the surgery | 
| Absence of endoleak after secondary connexion | Absence of Type 3 endoleak | early thereafter up to 5 years |
Hepatocellular Carcinoma Recurrence and Anesthesia

Study Overview
=================
Brief Summary
-----------------
The investigators will verify the prognosis of hepatocellular carcinoma (HCC) according to the main anesthetic agents used for the general anesthesia.

Conditions
-----------------
Hepatocellular Carcinoma

Intervention / Treatment
-----------------
* Other: Volatile anesthetics
* Other: Intravenous anesthetics


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Patients undergoing surgery due to the HCC. Exclusion Criteria: Patients undergoing re-operation due to the HCC. Patients presenting distant metastasis. Patients undergoing liver transplantation surgery.

Ages Eligible for Study
-----------------
Minimum Age: 20 Years
Maximum Age: 100 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Volatile<br>The investigators retrospectively reviewed and analyzed the electrical medical records of patients who underwent surgery for HCC under the general anesthesia using volatile anesthetics as maintenance agents. | Other: Volatile anesthetics<br> <br> |
| Intravenous<br>The investigators retrospectively reviewed and analyzed the electrical medical records of patients who underwent surgery for HCC under the general anesthesia using intravenous anesthetics as maintenance agents. | Other: Intravenous anesthetics<br> <br> |

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Recurrence of HCC |  | Postoperative 2 year |
Long-term Observation of Patients With Early Rheumatoid Arthritis

Study Overview
=================
Brief Summary
-----------------
The purpose of this research is to observe the effects of RA over a long period in order to learn which of the early characteristics of patients' early RA predict future joint damage and disability. We also investigate whether certain treatments can prevent or slow the development of joint damage and disability. Additionally, the costs and effects of RA on the patient are studied in order to improve the methods used to measure these effects. Clinical, demographic, radiographic, and laboratory measures are taken by the rheumatologist in the office. In addition, patient questionnaires are mailed & completed by the patient and returned to the coordinating center at UCLA. All information obtained by these means will be studied in their effects on early, severe RA.

Detailed Description
-----------------
See Publications

Official Title
-----------------
Long-term Observation of Patients With Early Rheumatoid Arthritis

Conditions
-----------------
Rheumatoid Arthritis

Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: >=6 swollen joints & >=9 tender joints symmetrical rheumatoid arthritis (RA) <= 2 years worth of symptoms rheumatoid factor seropositivity Exclusion Criteria: <18 years old Inability to see rheumatologist, complete questionnaires (lack of compliance) >2 years worth of symptoms

Ages Eligible for Study
-----------------
Minimum Age: 18 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------
What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Development of joint erosions in the early stages of RA | Measure joint erosions over time | Baseline, Annual Follow-up | 

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
Early, severe
Clinical Trial Evaluating the Optimal Technique for Chest Tube Removal

Study Overview
=================
Brief Summary
-----------------
There are two commonly used methods to remove chest tubes following thoracotomy. One is to remove the chest tube at maximum inspiration, (patient is asked to take a deep breath in and hold it), and the other is to pull the chest tube at maximum expiration,(patient is asked to blow out as much air as they can can and hold it). There has been considerable discussion among Thoracic surgeons that one of these two methods may decrease the risk of pneumothorax, the most common complication associated with chest tube removal. The investigators will compare the two methods, and also identify risk factors of developing pneumothorax during chest tube removal.

Official Title
-----------------
Randomized Clinical Trial Evaluating the Optimal Technique for Chest Tube Removal

Conditions
-----------------
Chest Tube Removal

Intervention / Treatment
-----------------
* Procedure: Chest tube pull on inspiration
* Procedure: Expiration


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Patients who are post thoracotomy, pulmonary resection (wedge, lobectomy, segmentectomy, pneumonectomy), AND Have at least one chest tube. Exclusion Criteria: Less than 19 years old, With interstitial lung disease, OR Any patient intubated.

Ages Eligible for Study
-----------------
Minimum Age: 19 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
Accepts Healthy Volunteers

Study Plan
=================
How is the study designed?
-----------------

Design Details

Primary Purpose: Treatment
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: None (Open Label)


Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Other: Inspiration<br> | Procedure: Chest tube pull on inspiration<br>* Pull chest tube on Inspiration<br>|
| Other: Expiration<br> | Procedure: Expiration<br>* Pull chest tube on Expiration<br>|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Pneumothorax |  | Within 4 hours after chest tube removal | 

Secondary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Morbidity |  | 4 hours after chest tube removal | 

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
Thoracotomy, Inspiration, Expiration, Chest Tube, pneumothorax, Method of chest tube removal
Observational Study of the Safety and Efficacy of Norditropin® in Patients With SGA (Small for Gestational Age) Short Stature That Are Still Growing

Study Overview
=================
Brief Summary
-----------------
This study is conducted in Japan. The aim of this observational study is to collect information about the safety and efficacy of Norditropin® in the long-term treatment of patients with a SGA (small for gestational age) short stature where the growth plate in the long bones (epiphyseal disc) is not closed. An extension to the GHLIQUID-1517 trial (NCT00184717).

Official Title
-----------------
A Multicentre, Open Label, Observational, Non-interventional Study to Evaluate on Long-term Safety and Efficacy of Norditropin® Formulation in Patients With SGA Short Stature Without Closure of Epiphyseal Discs

Conditions
-----------------
Foetal Growth Problem, Small for Gestational Age

Intervention / Treatment
-----------------
* Drug: somatropin


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Participation in the GHLIQUID-1517 trial Patients with SGA (small for gestational age) short stature that are still growing Exclusion Criteria: Known or suspected allergy to study product(s) or related products Diabetes Mellitus Patients with malignant tumor(s) Pregnant or likely to get pregnant
Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Norditropin®<br> | Drug: somatropin<br>* Norditropin® (somatropin) prescribed at the discretion of the physician according to normal clinical practice. Safety and effectiveness data is recorded by the physician, at study initiation and every 6 months until last visit.<br>|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Number and type of suspected serious adverse drug reactions (SADRs) during the study period |  | evaluated binannually for 9 years | 

Secondary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Number of glucose intolerance events during the study period |  | evaluated biannually for 9 years | 
| Adult height |  | Fulfilment will be evaluated once a year. Height when closure of ephiphyseal discs exists or when accomplished adult height is confirmed by physician |
Aripiprazole in the Treatment of Tourette's Syndrome

Study Overview
=================
Brief Summary
-----------------
This is an open-label, flexible dose study designed to evaluate the safety and efficacy of aripiprazole in TS (or chronic tic disorder) subjects with or without associated OC symptoms and with or without ADHD symptoms.

Detailed Description
-----------------
This is an open-label, flexible dose study designed to evaluate the safety and efficacy of aripiprazole in TS (or chronic tic disorder) subjects with or without associated OC symptoms and with or without ADHD symptoms.

Official Title
-----------------
Aripiprazole in the Treatment of Tourette's Syndrome

Conditions
-----------------
Tourette's Syndrome

Intervention / Treatment
-----------------
* Drug: Aripiprazole


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: DSM-IV primary diagnosis of Tourette's syndrome or chronic tic disorder; Moderate severity as reflected on the CGI or the YGTSS; Normal ECG; and, Written informed consent/assent. Exclusion Criteria: Female subjects of childbearing potential who are not practicing an effective method of birth control (including abstinence); Subjects who are pregnant or nursing women; Subjects with known seizure disorder, a history or seizures or with conditions that lower seizure threshold; Subjects who currently meet DSM-IV criteria for: Schizophrenia, Schizoaffective Disorder, Delusional Disorder, or Psychotic Disorder Not Otherwise Specified; Subjects with a Psychoactive Substance Abuse disorder (within the past 3 months); Subjects with known allergy or hypersensitivity to aripiprazole; Subjects who have any depot neuroleptic within one treatment cycle or any other changes in psychoactive medications (with the exception of antidepressants) in one month and two months for antidepressants prior to study entry for first administration of study medication; Subjects who have clinically significant abnormalities based on physical examination, medical history, ECG, or laboratory tests; and, Subjects on medication that pose drug interaction potential with aripiprazole such as carbamazepine, ketoconazole, paroxetine, and fluoxetine.

Ages Eligible for Study
-----------------
Minimum Age: 6 Years
Maximum Age: 17 Years

Sexes Eligible for Study
-----------------
All

Study Plan
=================
How is the study designed?
-----------------

Design Details

Primary Purpose: Treatment
Allocation: Non-Randomized
Intervention Model: Single Group Assignment
Masking: None (Open Label)


Arms and Interventions

| Intervention/Treatment |
| --- |
|Drug: Aripiprazole|nan|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Global improvement in severity of symptoms (tic behaviors) |  |  | 

Secondary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Assessment of behavior (improvement and severity) for co-morbid conditions, OCD and/or ADHD |  |  |
Intravenous Ascorbic Acid Administration in Hysterectomy

Study Overview
=================
Brief Summary
-----------------
vitamin C or ascorbic acid has known role in tissue repair. due to it's properties(water_soluble), vitamin c is not stored in the body and when depleted, the bleeding tendency will increase due to dysfunctional connective tissues production in vessel wall and it has some important functions in platelets.

Detailed Description
-----------------
In this randomized clinical trial, 1000 mg vitamin C will administrate intravenously a day before surgery and during surgery in patients who undergo abdominal hysterectomy.

Official Title
-----------------
Effect of Ascorbic Acid Administration on Intraoperative Blood Loss and Wound Healing in Total Abdominal Hysterectomy

Conditions
-----------------
Abdominal Hysterectomy

Intervention / Treatment
-----------------
* Drug: vitamin C


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: To be 18 years and older No smoking No history of bleeding disorder No history of favism No history of uterus, ovary, cervical cancer Exclusion Criteria: Need to injection of vasopressor drugs Surgeon disagreement

Ages Eligible for Study
-----------------
Minimum Age: 18 Years
Maximum Age: 65 Years

Sexes Eligible for Study
-----------------
Female

Accepts Healthy Volunteers
-----------------
Accepts Healthy Volunteers

Study Plan
=================
How is the study designed?
-----------------

Design Details

Primary Purpose: Prevention
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: None (Open Label)


Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Experimental: vitamin C<br>Intervention patients will be received double dose of Ascorbic acid via intravenous injection | Drug: vitamin C<br>* water-soluble vitamin C injection contain of 1000 mg vitamin C that given via intravenous injection<br>* Other names: ascorbic acid;|
| No Intervention: Control<br>Control patients will not be received any intervention | |

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| volume of hemorrhage | volume of hemorrhage during surgery | During surgery | 

Secondary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Hemoglobin value | Hemoglobin value after surgery | 6 and 24 hours after surgery | 
| wound healing | complications after surgery | during 2 weeks post surgery | 
| duration of stay in hospital | Length of stay in hospital | up to 2 weeks post surgery | 
| Infection | Developing infection up to 2 weeks | up to 2 weeks post surgery | 

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
vitamin c, Hysterectomy, bleeding, wound healing, abdominal surgeries
Effects of the Concentrated Extract of Soy on Coagulation Factors After Menopause

Study Overview
=================
Brief Summary
-----------------
Hypoestrogenism, common in menopause, is responsible for systemic and metabolic changes affecting women's wellness, favoring hot flashes, urogenital atrophy and bone mass loss. Hormone reposition therapy (HRT) with estrogen or estrogen associated to progesterone is administered to minimize these effects. Meanwhile, the beneficial effects of HRT are known, there is still concern about its adverse effects such as thromboembolic and cardiovascular effects, increased risk of breast and endometrial cancer. Thus, there is an increasing interest in the development of phytohormonal HRT. The aim of the investigators' study is to evaluate the effects of concentrated extract of soy on hypercoagulation markers in menopausal women.

Official Title
-----------------
Effects of the Concentrated Extract of Soy on Coagulation Factors After Menopause

Conditions
-----------------
Menopause

Intervention / Treatment
-----------------
* Drug: Isoflavone
* Drug: Placebo


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: > 1 year of amenorrhea 45 to 65 years old without hormone reposition treatment or herbal medications in the 6 months preceding the research Exclusion Criteria: history of thromboembolism history of cardiovascular disease presence of estrogen dependent neoplasia presence of abnormal genital bleeding uncontrolled metabolic diseases smoking or drinking habits use of anticoagulants or acetyl salicylic acid

Ages Eligible for Study
-----------------
Minimum Age: 45 Years
Maximum Age: 65 Years

Sexes Eligible for Study
-----------------
Female

Accepts Healthy Volunteers
-----------------
Accepts Healthy Volunteers

Study Plan
=================
How is the study designed?
-----------------

Design Details

Primary Purpose: Treatment
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Double


Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Experimental: Isoflavone<br>Patients will receive daily doses of 150 mg of concentrated extract of soy per os | Drug: Isoflavone<br>* 150 mg of concentrated extract of soy containing 60 mg of isoflavone comprising 40 mg of genistein, 14,55 mg of daidizein, 3,02 mg of daidzine, 1,14 mg of glicitine, 0,91 mg genistine and 0,38 mg of glicetein.<br>|
| Placebo Comparator: Control<br>Patients will receive daily placebo pills | Drug: Placebo<br>* Starch pill<br>|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Concentration of serum DDimer |  | 3 months | 

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
phytoestrogen, coagulation, menopause, ddimer, antithrombin, hypercoagulation
Evaluating Acupuncture Points With Scanning Kelvin Probe

Study Overview
=================
Brief Summary
-----------------
The purpose of this study is to characterize the surface electrical potential of acupuncture points with a Scanning Kelvin Probe.

Detailed Description
-----------------
Acupuncture points are anatomical structures described by traditional Chinese medicine. To this day, however, their scientific and Western anatomical characterizations remain unclear. Past studies have suggested that acupuncture points are distinct electrically (increased electrical conductivity). To evaluate this claim, this study uses a Scanning Kelvin Probe to study the electrical potential of three acupuncture points and their respective adjacent controls in 24 healthy individuals. The Scanning Kelvin Probe is a novel device that measures the electrical potential of skin without actually touching the skin surface.

Official Title
-----------------
Scanning Kelvin Probe Measurements of Acupuncture Point

Conditions
-----------------
Healthy Individuals, Acupuncture Points, Electrical Potential

Intervention / Treatment
-----------------
* Other: not applicable in this study


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Individuals without chronic medical condition requiring daily medications (hypertension, diabetes, hypothyroidism, etc). Exclusion Criteria: Individuals with autonomic disorders (sweating irregularities), skin disorders, extensive burns/scars on the hand, tremors, neuromuscular conditions, restless leg syndrome, movement disorders, and implanted cardiac defibrillator/pacemaker

Ages Eligible for Study
-----------------
Minimum Age: 18 Years
Maximum Age: 65 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
Accepts Healthy Volunteers

Study Plan
=================
How is the study designed?
-----------------

Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Healthy Volunteers<br> | Other: not applicable in this study<br>* No actual interventions will be administered for this study.<br>|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Electrical Potential at Acupuncture points | Scanning Kelvin Probe measurements of electrical potentials at 3 predetermined acupuncture points. | One day |